Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor
Abstract
Immune checkpoint inhibitors have achieved clinical success in cancer treatment, but this treatment causes immune‐related adverse events, including type 1 diabetes (T1D). Our aim was to test whether a JAK1/JAK2 inhibitor, effective at treating spontaneous autoimmune diabetes in nonobese diabetic (NOD) mice, can prevent diabetes secondary to PD‐L1 blockade.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2022
- Source ID
- 10.1002/cti2.1425
Entities
People
- Amber‐lee Phung
- Balasubramanian Krishnamurthy
- David J De George
- Evan G Pappas
- Gaurang Jhala
- Helen Thomas
- Jonathan Chee
- Laura Sanz-Villanueva
- Louis Boon
- Nicola Principe
- Prerak Trivedi
- Sara Litwak
- Stacey Fynch
- Tara Catterall
- Thomas W Kay
- Tingting Ge
Organizations
- Cancer Council Australia
- Mesothelioma Applied Research Foundation
- National Health and Medical Research Council
- United States Department of Defense
- University of Melbourne
- University of Western Australia